Download PDF
Horm Metab Res 2014; 46(09): 656-662
DOI: 10.1055/s-0034-1381998
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Growth Hormone Ameliorates Adipose Dysfunction During Oxidative Stress and Inflammation and Improves Glucose Tolerance in Obese Mice

M. Fukushima
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
,
Y. Okamoto
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
2   Division of Endocrinology, Diabetology and Atherosclerosis Medicine, Nippon Medical School Musashi-kosugi Hospital, Kawasaki, Kanagawa, Japan
,
H. Katsumata
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
,
M. Ishikawa
2   Division of Endocrinology, Diabetology and Atherosclerosis Medicine, Nippon Medical School Musashi-kosugi Hospital, Kawasaki, Kanagawa, Japan
,
S. Ishii
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
,
M. Okamoto
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
,
S. Minami
1   Department of Bioregulation, Nippon Medical School, Kawasaki, Kanagawa, Japan
2   Division of Endocrinology, Diabetology and Atherosclerosis Medicine, Nippon Medical School Musashi-kosugi Hospital, Kawasaki, Kanagawa, Japan
› Author Affiliations
Further Information

Publication History

received 10 October 2013

accepted 13 May 2014

Publication Date:
04 July 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Patients with adult growth hormone deficiency exhibit visceral fat accumulation, which gives rise to a cluster of metabolic disorders such as impaired glucose tolerance and dyslipidemia. Plasma growth hormone levels are lower in obese patients with metabolic syndrome than in healthy subjects. Here we examined the hypothesis that exogenous growth hormone administration regulates function of adipose tissue to improve glucose tolerance in diet-induced obese mice. Twelve-week-old obese male C57BL/6 J mice received bovine growth hormone daily for 6 weeks. In epididymal fat, growth hormone treatment antagonized diet-induced changes in the gene expression of adiponectin, leptin, and monocyte chemoattractant protein-1, and significantly increased the gene expression of interleukin-10 and CD206. Growth hormone also suppressed the accumulation of oxidative stress marker, thiobarbituric acid-reactive substances, in the epididymal fat and enhanced the gene expression of anti-oxidant enzymes. Moreover, growth hormone significantly restored glucose tolerance in obese mice. In cultured 3T3-L1 adipocytes, growth hormone prevented the decline in adiponectin gene expression in the presence of hydrogen peroxide. These results suggest that growth hormone administration ameliorates glucose intolerance in obese mice presumably by decreasing adipose mass, oxidative stress, and chronic inflammation in the visceral fat.

Key words

growth hormone - adipose tissue - oxidative stress - inflammation - adiponectin - glucose tolerance

Supporting Information

 

  • References

  • 1 Beshyah SA, Freemantle C, Thomas E, Rutherford O, Page B, Murphy M, Johnston DG. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995; 42: 179-189
    CrossrefPubMedGoogle Scholar
  • 2 Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-395
    CrossrefPubMedGoogle Scholar
  • 3 Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ, Bouillon R, Crowe B, Selander K, Valle D, Lamberts SW. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status – 3-year results from the HypoCCS Database. J Clin Endocrinol Metab 2002; 87: 1600-1606
    CrossrefPubMedGoogle Scholar
  • 4 Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO, Vance ML. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2048-2056
    CrossrefPubMedGoogle Scholar
  • 5 Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011; 18: 629-639
    CrossrefPubMedGoogle Scholar
  • 6 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
    CrossrefPubMedGoogle Scholar
  • 7 Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278
    CrossrefPubMedGoogle Scholar
  • 8 Friedman JM. Obesity: Causes and control of excess body fat. Nature 2009; 459: 340-342
    CrossrefPubMedGoogle Scholar
  • 9 Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867
    CrossrefPubMedGoogle Scholar
  • 10 Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761
    CrossrefPubMedGoogle Scholar
  • 11 Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788
    CrossrefPubMedGoogle Scholar
  • 12 Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800
    CrossrefPubMedGoogle Scholar
  • 13 Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51-59
    CrossrefPubMedGoogle Scholar
  • 14 Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663
    CrossrefPubMedGoogle Scholar
  • 15 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099
    CrossrefPubMedGoogle Scholar
  • 16 Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47: 556-564
    CrossrefPubMedGoogle Scholar
  • 17 Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol 2008; 154: 557-568
    CrossrefPubMedGoogle Scholar
  • 18 Ding J, List EO, Bower BD, Kopchick JJ. Differential effects of growth hormone versus insulin-like growth factor-I on the mouse plasma proteome. Endocrinology 2011; 152: 3791-3802
    CrossrefPubMedGoogle Scholar
  • 19 Bielohuby M, Schaab M, Kummann M, Sawitzky M, Gebhardt R, Binder G, Frystyk J, Bjerre M, Hoeflich A, Kratzsch J, Bidlingmaier M. Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice. Endocrinology 2011; 152: 4764-4776
    CrossrefPubMedGoogle Scholar
  • 20 Lubbers ER, List EO, Jara A, Sackman-Sala L, Cordoba-Chacon J, Gahete MD, Kineman RD, Boparai R, Bartke A, Kopchick JJ, Berryman DE. Adiponectin in mice with altered GH action: links to insulin sensitivity and longevity?. J Endocrinol 2013; 216: 363-374
    CrossrefPubMedGoogle Scholar
  • 21 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830
    CrossrefPubMedGoogle Scholar
  • 22 Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505
    CrossrefPubMedGoogle Scholar
  • 23 Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K, Nagai Y, Takatsu K, Urakaze M, Kobayashi M, Tobe K. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009; 58: 2574-2582
    CrossrefPubMedGoogle Scholar
  • 24 Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-2049
    CrossrefPubMedGoogle Scholar
  • 25 Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160
    CrossrefPubMedGoogle Scholar
  • 26 Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917-2921
    CrossrefPubMedGoogle Scholar
  • 27 Wu Y, Liu C, Sun H, Vijayakumar A, Giglou PR, Qiao R, Oppenheimer J, Yakar S, LeRoith D. Growth hormone receptor regulates beta cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest 2011; 121: 2422-2426
    CrossrefPubMedGoogle Scholar
  • 28 Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 2007; 13: 363-372
    CrossrefPubMedGoogle Scholar
  • 29 Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, Bonaduce D, Salvatore M, Lombardi G. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002; 87: 3097-3104
    CrossrefPubMedGoogle Scholar
  • 30 Frick F, Bohlooly-Y M, Lindén D, Olsson B, Törnell J, Edén S, Oscarsson J. Long-term growth hormone excess induces marked alterations in lipoprotein metabolism in mice. Am J Physiol Endocrinol Metab 2001; 281: E1230-E1239
    PubMedGoogle Scholar
  • 31 Olsson B, Bohlooly-Y M, Fitzgerald SM, Frick F, Ljungberg A, Ahrén B, Törnell J, Bergström G, Oscarsson J. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 2005; 146: 920-930
    CrossrefPubMedGoogle Scholar
  • 32 Møller N, Jørgensen JO, Schmitz O, Møller J, Christiansen J, Alberti KG, Orskov H. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 1990; 258: E86-E91
    PubMedGoogle Scholar
  • 33 Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, Ye HY, Lam KS, Xu A. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011; 286: 34559-34566
    CrossrefPubMedGoogle Scholar
  • 34 List EO, Palmer AJ, Berryman DE, Bower B, Kelder B, Kopchick JJ. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia 2009; 52: 1647-1655
    CrossrefPubMedGoogle Scholar
  • 35 Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009; 15: 1082-1087
    CrossrefPubMedGoogle Scholar